CD274 and gastric adenocarcinoma: Additionally, FDA approved pembrolizumab for the 2-line treatment for the patients with SCC with CPS ≥ 10 and for the 3-line treatment for the patients of with GEJ and gastric adenocarcinoma with PD-L1 CPS ≥ 1.